Stammdaten
Cytokinetics, Incorporated, ein fortgeschrittenes biopharmazeutisches Unternehmen, konzentriert sich auf die Entdeckung, Entwicklung und Vermarktung von Muskelaktivatoren und -inhibitoren als potenzielle Behandlungen für schwächende Krankheiten. Das Unternehmen entwickelt hauptsächlich kleine Moleküle-Wirkstoffkandidaten, die auf die Beeinflussung der Muskelfunktion und Kontraktilität ausgerichtet sind. Die Wirkstoffkandidaten umfassen Omecamtiv Mecarbil, einen neuartigen kardialen Myosin-Aktivator, der sich in Phase III Klinikversuchen bei Patienten mit Herzinsuffizienz befindet; und Reldesemtiv, einen Skelettmuskel-Troponin-Aktivator, der sich in Phase III Klinikversuchen zur Behandlung von amyotropher Lateralsklerose und spinaler Muskelatrophie befindet. Das Unternehmen entwickelt auch CK-136, einen neuartigen kardialen Troponin-Aktivator, der sich in Phase I Klinikversuchen befindet; Aficamten, einen neuartigen kardialen Myosin-Inhibitor, der sich in Phase III Klinikversuchen zur Behandlung von Patienten mit symptomatischer obstruktiver hypertrophischer Kardiomyopathie befindet; und CK-3772271, einen kleinen Moleküle-Inhibitor für kardiales Myosin, der sich in Phase I Klinikversuchen befindet. Cytokinetics, Incorporated hat eine strategische Allianz mit Astellas Pharma Inc. Das Unternehmen wurde 1997 gegründet und hat seinen Hauptsitz in South San Francisco, Kalifornien. KI
Unternehmen & Branche
| Name | CYTOKINETICS INC |
|---|---|
| Ticker | CYTK |
| CIK | 0001061983 |
| Börse | Nasdaq |
| Sektor | Gesundheit |
| Industrie | Pharmazeutische Erzeugnisse |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 23282W605 |
|---|---|
| ISIN | US23282W6057 |
| Typ | Common Stock |
| Marktkapitalisierung | 9,93 Mrd. USD |
| Beta | 0,34 |
Sitz & Kontakt
| Geschäftsadresse | 350 OYSTER POINT BOULEVARD ., 94080 SOUTH SAN FRANCISCO, CA |
|---|---|
| Telefon | (650) 624-3000 |
| EIN (IRS) | 94-3291317 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
Bewertung
| KUV (P/S) | 112,75 vs. 54,88 (2021) ▲ |
|---|---|
| FCF-Rendite | -5,4 % vs. -5,0 % (2021) ▼ |
Qualität & Bilanz
| Operative Marge | -695,4 % vs. -264,5 % (2021) ▼ |
|---|---|
| Nettomarge | -891,6 % vs. -305,7 % (2021) ▼ |
| Zinsdeckungsgrad | -13,4 vs. -11,3 (2021) ▼ |
| Forderungslaufzeit (DSO) | 74 T vs. 269 T (2021) ▼ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KUV (P/S) | 54,88 | 45,94 | 1.126,93 | 300,99 | 88,73 | 93,81 | |
| FCF-Rendite | -5,0 % | -7,2 % | -4,9 % | -7,2 % | -6,8 % | -5,5 % | |
| Qualität & Bilanz | |||||||
| Operative Marge | -264,5 % | -342,8 % | -6.589,7 % | -2.902,7 % | -695,4 % | -605,1 % | |
| Nettomarge | -305,7 % | -411,2 % | -6.988,6 % | -3.191,1 % | -891,6 % | -784,0 % | |
| ROIC | -51,5 % | -402,7 % | – | -584,1 % | – | – | |
| Zinsdeckungsgrad | -11,3 | -16,7 | -17,5 | -14,2 | -13,4 | – | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
CYTK
CYTOKINETICS INC
Effektiv
Schwach
Handelsvolumen
Hoch
Insider
0,0
Keine Insider-Käufe
Institutionell
44,4
77 neu, 187 erhöht, 808,9M $ netto
Aktivist
17,8
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 78.40 | +2.8 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 67.56 | +19.3 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 81.32 | EMA50: 78.32 | |
| MACD-Histogramm | Bärisch | 10 % | -0.648 | Bearisch | |
| RSI(14) | Neutral | 10 % | 49.6 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 28.7 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 22.6 | +DI: 18.4 / −DI: 14.4 | |
| Z-Score(60) | Neutral | 5 % | 0.56 | In Range | |
| 52W-Position | Bullisch | 5 % | 87.7 % | Hoch 87.26 / Tief 33.23 | |
| Bollinger(20,2σ) | Neutral | 5 % | 23.3 % | Upper 88.05 / Mid 83.21 / Lower 78.37 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.2174 | R²=0.42 / annualisiert +70.8 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-27 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -7.500 | 80,87 | -606.525,00 | -123,1% | |
| 2026-07-21 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -3.500 | 80,59 | -282.065,00 | -57,2% | |
| 2026-07-13 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -7.490 | 82,02 | -614.329,80 | -124,6% | |
| 2026-07-13 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -10 | 82,02 | -820,20 | -0,2% | |
| 2026-07-07 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -3.500 | 86,62 | -303.170,00 | -61,5% | |
| 2026-07-01 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -15.000 | 85,80 | -1.287.000,00 | -261,1% | |
| 2026-07-01 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -7.500 | 84,92 | -636.900,00 | -129,2% | |
| 2026-07-01 | Lee Sung | Officer, EVP, Chief Financial Officer | Open Market Sale | -1.112 | 87,79 | -97.622,48 | -19,8% | |
| 2026-06-29 | Lee Sung | Officer, EVP, Chief Financial Officer | Open Market Sale | -3.134 | 85,00 | -266.390,00 | -54,0% | |
| 2026-06-24 | Lee Sung | Officer, EVP, Chief Financial Officer | Open Market Sale | -38.730 | 82,30 | -3.187.479,00 | -646,7% | |
| 2026-06-23 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -3.500 | 79,51 | -278.285,00 | -56,5% | |
| 2026-06-15 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -7.500 | 70,46 | -528.450,00 | -107,2% | |
| 2026-06-09 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -3.500 | 67,98 | -237.930,00 | -48,3% | |
| 2026-06-01 | PARSHALL B LYNNE | Director | Open Market Sale | -5.000 | 74,08 | -370.400,00 | -75,2% | |
| 2026-06-01 | Kaye Edward M. MD | Director | Open Market Sale | -2.933 | 76,09 | -223.171,97 | -45,3% | |
| 2026-06-01 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -15.000 | 74,08 | -1.111.200,00 | -225,5% | |
| 2026-05-27 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -7.500 | 77,21 | -579.075,00 | -117,5% | |
| 2026-05-19 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -3.500 | 75,69 | -264.915,00 | -53,7% | |
| 2026-05-14 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -7.500 | 77,92 | -584.400,00 | -118,6% | |
| 2026-05-05 | HENDERSON JOHN T | Director | Open Market Sale | -20.000 | 75,97 | -1.519.400,00 | -308,3% | |
| 2026-05-05 | Lee Sung | Officer, EVP, Chief Financial Officer | Open Market Sale | -23.906 | 76,87 | -1.837.654,22 | -372,8% | |
| 2026-05-05 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -3.500 | 77,37 | -270.795,00 | -54,9% | |
| 2026-05-05 | WIERENGA WENDELL | Director | Open Market Sale | -4.032 | 75,00 | -302.400,00 | -61,4% | |
| 2026-05-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -11.333 | 77,25 | -875.474,25 | -177,6% | |
| 2026-05-01 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -15.857 | 65,00 | -1.030.705,00 | -209,1% | |
| 2026-04-30 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -15.000 | 63,26 | -948.900,00 | -192,5% | |
| 2026-04-29 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -7.500 | 59,62 | -447.150,00 | -90,7% | |
| 2026-04-21 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -3.500 | 65,69 | -229.915,00 | -46,6% | |
| 2026-04-15 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -7.500 | 65,38 | -490.350,00 | -99,5% | |
| 2026-04-15 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -7.449 | 66,02 | -491.782,98 | -99,8% | |
| 2026-04-07 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -3.500 | 65,21 | -228.235,00 | -46,3% | |
| 2026-04-07 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -1.000 | 64,75 | -64.750,00 | -13,1% | |
| 2026-04-01 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -7.500 | 66,63 | -499.725,00 | -101,4% | |
| 2026-03-31 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -3.639 | 65,00 | -236.535,00 | -48,0% | |
| 2026-03-18 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -1.930 | 62,07 | -119.795,10 | -24,3% | |
| 2026-03-17 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2.916 | 62,15 | -181.229,40 | -36,8% | |
| 2026-03-17 | Lee Sung | Officer, EVP, Chief Financial Officer | Open Market Sale | -4.935 | 62,15 | -306.710,25 | -62,2% | |
| 2026-03-17 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -23.928 | 62,15 | -1.487.125,20 | -301,7% | |
| 2026-03-17 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -12.673 | 62,15 | -787.626,95 | -159,8% | |
| 2026-03-17 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -4.397 | 62,15 | -273.273,55 | -55,4% | |
| 2026-03-17 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -5.626 | 62,15 | -349.655,90 | -70,9% | |
| 2026-03-17 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -7.636 | 62,15 | -474.577,40 | -96,3% | |
| 2026-03-16 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -1.709 | 61,03 | -104.300,27 | -21,2% | |
| 2026-03-09 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2.582 | 60,72 | -156.779,04 | -31,8% | |
| 2026-03-09 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.907 | 60,72 | -176.513,04 | -35,8% | |
| 2026-03-09 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -7.931 | 60,72 | -481.570,32 | -97,7% | |
| 2026-03-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -11.000 | 61,88 | -680.680,00 | -138,1% | |
| 2026-03-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -15.000 | 61,87 | -928.050,00 | -188,3% | |
| 2026-03-02 | PARSHALL B LYNNE | Director | Open Market Sale | -5.000 | 61,21 | -306.050,00 | -62,1% | |
| 2026-03-02 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -886 | 61,62 | -54.595,32 | -11,1% | |
| 2026-02-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -15.000 | 61,93 | -928.950,00 | -188,5% | |
| 2026-02-02 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -886 | 62,10 | -55.020,60 | -11,2% | |
| 2026-01-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -15.000 | 60,28 | -904.200,00 | -183,5% | |
| 2026-01-02 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -885 | 63,16 | -55.896,60 | -11,3% | |
| 2026-01-02 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -913 | 62,09 | -56.688,17 | -11,5% | |
| 2025-12-29 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -1.809 | 62,44 | -112.953,96 | -22,9% | |
| 2025-12-22 | WIERENGA WENDELL | Director | Open Market Sale | -20.000 | 66,14 | -1.322.800,00 | -268,4% | |
| 2025-12-16 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.200 | 61,24 | -134.728,00 | -27,3% | |
| 2025-12-08 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -1.042 | 65,96 | -68.730,32 | -13,9% | |
| 2025-12-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -52.486 | 65,95 | -3.461.451,70 | -702,3% | |
| 2025-12-02 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.200 | 63,89 | -140.558,00 | -28,5% | |
| 2025-12-02 | HENDERSON JOHN T | Director | Open Market Sale | -8.750 | 63,90 | -559.125,00 | -113,4% | |
| 2025-12-01 | Harrington Robert Arthur | Director | Open Market Sale | -2.150 | 66,80 | -143.620,00 | -29,1% | |
| 2025-12-01 | Kaye Edward M. MD | Director | Open Market Sale | -28.064 | 66,72 | -1.872.430,08 | -379,9% | |
| 2025-11-19 | PARSHALL B LYNNE | Director | Open Market Sale | -5.000 | 64,73 | -323.650,00 | -65,7% | |
| 2025-11-18 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.200 | 66,45 | -146.190,00 | -29,7% | |
| 2025-11-11 | Kaye Edward M. MD | Director | Open Market Sale | -5.175 | 65,08 | -336.789,00 | -68,3% | |
| 2025-11-04 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.295 | 59,55 | -136.667,25 | -27,7% | |
| 2025-10-30 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5.000 | 62,86 | -314.300,00 | -63,8% | |
| 2025-10-27 | WIERENGA WENDELL | Director | Open Market Sale | -4.375 | 58,68 | -256.725,00 | -52,1% | |
| 2025-10-21 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.105 | 58,22 | -122.553,10 | -24,9% | |
| 2025-10-16 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5.000 | 60,03 | -300.150,00 | -60,9% | |
| 2025-10-07 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.000 | 60,56 | -121.120,00 | -24,6% | |
| 2025-10-06 | Kaye Edward M. MD | Director | Open Market Sale | -6.757 | 60,00 | -405.420,00 | -82,3% | |
| 2025-10-01 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5.000 | 55,05 | -275.250,00 | -55,8% | |
| 2025-09-30 | Kaye Edward M. MD | Director | Open Market Sale | -6.695 | 55,08 | -368.760,60 | -74,8% | |
| 2025-09-23 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.000 | 49,28 | -98.560,00 | -20,0% | |
| 2025-09-15 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5.000 | 49,77 | -248.850,00 | -50,5% | |
| 2025-09-09 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.000 | 51,29 | -102.580,00 | -20,8% | |
| 2025-09-02 | Kaye Edward M. MD | Director | Open Market Sale | -6.756 | 50,00 | -337.800,00 | -68,5% | |
| 2025-09-02 | Harrington Robert Arthur | Director | Open Market Sale | -2.150 | 48,67 | -104.640,50 | -21,2% | |
| 2025-09-02 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5.000 | 48,76 | -243.800,00 | -49,5% | |
| 2025-08-19 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.000 | 38,31 | -76.620,00 | -15,5% | |
| 2025-08-15 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5.000 | 38,42 | -192.100,00 | -39,0% | |
| 2025-08-05 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.000 | 36,34 | -72.680,00 | -14,7% | |
| 2025-07-29 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5.000 | 36,45 | -182.250,00 | -37,0% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 16.548.011 | 0 | 16.548.011 | 1.090.679.433 | Neu | +100,0% | |
| FMR LLC | 23.263.140 | 0 | 23.263.140 | 725.086.240 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 13.199.489 | 0 | 13.199.489 | 535.490.690 | Neu | +100,0% | |
| STATE STREET CORP | 5.745.193 | 0 | 5.745.193 | 378.665.671 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.488.634 | 0 | 5.488.634 | 361.755.867 | Neu | +100,0% | |
| Avoro Capital Advisors LLC | 3.333.333 | 0 | 3.333.333 | 219.699.978 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 8.283.436 | 0 | 8.283.436 | 213.534.616 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 3.215.415 | 0 | 3.215.415 | 211.965.492 | Neu | +100,0% | |
| RTW INVESTMENTS, LP | 2.721.158 | 0 | 2.721.158 | 179.351.524 | Neu | +100,0% | |
| ARMISTICE CAPITAL, LLC | 2.664.538 | 0 | 2.664.538 | 175.619.700 | Neu | +100,0% | |
| Integral Health Asset Management, LLC | 2.600.000 | 0 | 2.600.000 | 171.366.000 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 4.265.758 | 0 | 4.265.758 | 164.503.872 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2.222.751 | 0 | 2.222.751 | 146.501.518 | Neu | +100,0% | |
| UBS Group AG | 2.102.177 | 0 | 2.102.177 | 138.554.486 | Neu | +100,0% | |
| BALYASNY ASSET MANAGEMENT L.P. | 36.742.145 | 0 | 36.742.145 | 124.443.571 | Neu | +100,0% | |
| Caption Management, LLC | 1.856.600 | 0 | 1.856.600 | 122.368.506 | Neu | +100,0% | |
| Polar Capital Holdings Plc | 1.661.248 | 0 | 1.661.248 | 109.492.856 | Neu | +100,0% | |
| MORGAN STANLEY | 4.666.075 | 0 | 4.666.075 | 103.818.602 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 1.554.358 | 0 | 1.554.358 | 102.447.736 | Neu | +100,0% | |
| Paradigm Biocapital Advisors LP | 1.480.857 | 0 | 1.480.857 | 97.603.285 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 1.441.634 | 0 | 1.441.634 | 95.018.097 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.397.045 | 0 | 1.397.045 | 92.079.236 | Neu | +100,0% | |
| Deep Track Capital, LP | 1.374.320 | 0 | 1.374.320 | 90.581.431 | Neu | +100,0% | |
| Capital International Investors | 1.338.803 | 0 | 1.338.803 | 88.240.506 | Neu | +100,0% | |
| LMR Partners LLP | 12.607.800 | 0 | 12.607.800 | 85.339.473 | Neu | +100,0% | |
| Ikarian Capital, LLC | 1.242.472 | 0 | 1.242.472 | 81.891.330 | Neu | +100,0% | |
| Frazier Life Sciences Management, L.P. | 1.159.879 | 0 | 1.159.879 | 76.447.625 | Neu | +100,0% | |
| PRINCIPAL FINANCIAL GROUP INC | 1.093.485 | 0 | 1.093.485 | 72.071.596 | Neu | +100,0% | |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.087.591 | 0 | 1.087.591 | 71.683.123 | Neu | +100,0% | |
| Woodline Partners LP | 1.000.428 | 0 | 1.000.428 | 65.938.209 | Neu | +100,0% | |
| Royalty Pharma Sub-Manager, LLC | 980.392 | 0 | 980.392 | 64.617.637 | Neu | +100,0% | |
| GROUP ONE TRADING LLC | 948.097 | 0 | 948.097 | 62.489.073 | Neu | +100,0% | |
| CAPSTONE INVESTMENT ADVISORS, LLC | 13.631.000 | 0 | 13.631.000 | 61.247.738 | Neu | +100,0% | |
| Logos Global Management LP | 875.000 | 0 | 875.000 | 57.671.250 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 854.374 | 0 | 854.374 | 56.311.790 | Neu | +100,0% | |
| Melqart Asset Management (UK) Ltd | 843.949 | 0 | 843.949 | 55.624.679 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 779.446 | 0 | 779.446 | 51.373.286 | Neu | +100,0% | |
| Capital Research Global Investors | 770.999 | 0 | 770.999 | 50.816.544 | Neu | +100,0% | |
| BNP Paribas Asset Management Holding S.A. | 3.214.344 | 0 | 3.214.344 | 50.778.273 | Neu | +100,0% | |
| Fisher Asset Management, LLC | 768.264 | 0 | 768.264 | 50.636.280 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 750.953 | 0 | 750.953 | 49.297.191 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 747.331 | 0 | 747.331 | 49.256.586 | Neu | +100,0% | |
| Affinity Asset Advisors, LLC | 700.483 | 0 | 700.483 | 46.168.835 | Neu | +100,0% | |
| FEDERATED HERMES, INC. | 699.453 | 0 | 699.453 | 46.100.947 | Neu | +100,0% | |
| Nuveen, LLC | 14.351.809 | 0 | 14.351.809 | 43.645.232 | Neu | +100,0% | |
| Point72 Asset Management, L.P. | 661.002 | 0 | 661.002 | 43.566.642 | Neu | +100,0% | |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | 660.310 | 0 | 660.310 | 43.521.032 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 656.608 | 0 | 656.608 | 43.277.032 | Neu | +100,0% | |
| ADAR1 Capital Management, LLC | 632.556 | 0 | 632.556 | 41.691.766 | Neu | +100,0% | |
| BROWN ADVISORY INC | 614.655 | 0 | 614.655 | 40.511.918 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| E. Ohman J:or Asset Management AB | 304.611 | 300.762 | +1,3% | 25.949.811 | 16,14 | 100 % | 6 Q |
| Polaris Capital Management, LLC | 266.900 | 0 | +100,0% | 22.737.211 | 14,14 | 100 % | 1 Q |
| Mirador Capital Partners LP | 202.370 | 202.673 | -0,1% | 17.239.900 | 10,72 | 100 % | 17 Q |
| Retirement Systems of Alabama | 140.426 | 149.891 | -6,3% | 11.962.891 | 7,44 | 100 % | 10 Q |
| Erste Asset Management GmbH | 109.183 | 76.950 | +41,9% | 9.527.309 | 5,93 | 25 % | 17 Q |
| PEREGRINE CAPITAL MANAGEMENT LLC | 100.019 | 103.626 | -3,5% | 8.520.619 | 5,30 | 37 % | 17 Q |
| Capricorn Fund Managers Ltd | 81.879 | 0 | +100,0% | 6.975.272 | 4,34 | 100 % | 1 Q |
| NEW YORK STATE COMMON RETIREMENT FUND | 72.682 | 46.719 | +55,6% | 6.191.780 | 3,85 | 100 % | 17 Q |
| ACT CAPITAL MANAGEMENT, LLC | 47.500 | 64.500 | -26,4% | 4.046.525 | 2,52 | 100 % | 3 Q |
| Y-Intercept (Hong Kong) Ltd | 43.619 | 0 | +100,0% | 3.715.903 | 2,31 | 100 % | 5 Q |
| Louisiana State Employees Retirement System | 39.700 | 35.500 | +11,8% | 3.382.043 | 2,10 | 100 % | 17 Q |
| Police & Firemen's Retirement System of New Jersey | 39.014 | 32.776 | +19,0% | 3.323.603 | 2,07 | 100 % | 7 Q |
| YOUSIF CAPITAL MANAGEMENT, LLC | 38.651 | 36.919 | +4,7% | 3.292.679 | 2,05 | 32 % | 17 Q |
| OAK RIDGE INVESTMENTS LLC | 32.518 | 15.902 | +104,5% | 2.770.208 | 1,72 | 88 % | 9 Q |
| COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS | 32.504 | 30.634 | +6,1% | 2.769.016 | 1,72 | 100 % | 17 Q |
| MOODY ALDRICH PARTNERS LLC | 28.963 | 36.945 | -21,6% | 2.467.358 | 1,53 | 44 % | 14 Q |
| OREGON PUBLIC EMPLOYEES RETIREMENT FUND | 28.015 | 25.115 | +11,5% | 2.386.598 | 1,48 | 100 % | 17 Q |
| Context Capital Management, LLC | 1.386.000 | 1.386.000 | 0,0% | 2.359.492 | 1,47 | 100 % | 7 Q |
| TEMA ETFS LLC | 22.413 | 8.162 | +174,6% | 1.909.363 | 1,19 | 100 % | 7 Q |
| China Universal Asset Management Co., Ltd. | 21.577 | 21.856 | -1,3% | 1.838.145 | 1,14 | 100 % | 16 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 101 | 3,9 | 163 |
| 31.03.2026 | ✓ | 444 | 294,5 | 9.003 |
| 31.12.2025 | ✓ | 436 | 318,8 | 8.406 |
| 30.09.2025 | ✓ | 392 | 336,4 | 7.132 |
| 30.06.2025 | ✓ | 328 | 676,2 | 4.463 |
| 31.03.2025 | ✓ | 369 | 686,7 | 5.956 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| Avoro Capital Advisors LLC | 3.333.333 | 219.699.978 |
| Paradigm Biocapital Advisors LP | 1.480.857 | 97.603.285 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.087.591 | 71.683.123 |
| Capital Research Global Investors | 770.999 | 50.816.544 |
| Point72 Asset Management, L.P. | 626.102 | 41.266.383 |
| Siren, L.L.C. | 613.952 | 40.465.576 |
| MPM BioImpact LLC | 500.000 | 32.955.000 |
| Vestal Point Capital, LP | 300.000 | 19.773.000 |
| Trails Edge Capital Partners, LP | 300.000 | 19.773.000 |
| Capital World Investors | 242.041 | 15.952.922 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| Nuveen, LLC | 14.351.809 | 8.982.530 | +167.3 % | 43.645.232 |
| TWO SIGMA INVESTMENTS, LP | 14.055.008 | 5.280.991 | +60.2 % | 38.906.290 |
| Jefferies Financial Group Inc. | 5.370.000 | 1.150.000 | +27.3 % | 7.926.394 |
| BALYASNY ASSET MANAGEMENT L.P. | 36.636.545 | 992.545 | +2.8 % | 117.483.475 |
| UBS Group AG | 2.077.277 | 945.821 | +83.6 % | 136.913.327 |
| D. E. Shaw & Co., Inc. | 706.631 | 587.410 | +492.7 % | 46.574.049 |
| Logos Global Management LP | 875.000 | 575.000 | +191.7 % | 57.671.250 |
| MARSHALL WACE, LLP | 656.608 | 319.577 | +94.8 % | 43.277.032 |
| BNP PARIBAS FINANCIAL MARKETS | 854.374 | 274.512 | +47.3 % | 56.311.790 |
| Qube Research & Technologies Ltd | 779.446 | 242.169 | +45.1 % | 51.373.286 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | 8.283.436 | -14.096.716 | -63.0 % | 213.534.616 |
| FMR LLC | 23.263.140 | -13.429.612 | -36.6 % | 725.086.240 |
| GOLDMAN SACHS GROUP INC | 4.015.758 | -2.265.921 | -36.1 % | 148.026.372 |
| Deep Track Capital, LP | 1.374.320 | -1.962.678 | -58.8 % | 90.581.431 |
| BNP Paribas Asset Management Holding S.A. | 3.214.344 | -763.519 | -19.2 % | 50.778.273 |
| Polar Capital Holdings Plc | 1.661.248 | -761.364 | -31.4 % | 109.492.856 |
| Woodline Partners LP | 1.000.428 | -648.000 | -39.3 % | 65.938.209 |
| ADVENT CAPITAL MANAGEMENT /DE/ | 1.140.000 | -610.000 | -34.9 % | 1.679.220 |
| MORGAN STANLEY | 4.666.075 | -554.226 | -10.6 % | 103.818.602 |
| LAZARD ASSET MANAGEMENT LLC | 11.417.369 | -409.631 | -3.5 % | 257.390 |
Zusätzlich aktuell von 230 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 08.07.2026 | Abigail P. Johnson (+1) | Passiv (13G/A) | 3,90 % | 5.248.580 | -5,10 pp | |
| 06.05.2026 | Abigail P. Johnson (+1) | Passiv (13G/A) | 9,00 % | 11.135.192 | -1,90 pp | |
| 30.04.2026 | Vanguard Capital Management | Passiv (13G) | 5,21 % | 6.422.042 | Neu | |
| 26.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -10,09 pp | |
| 17.02.2026 | T. Rowe Price Investment Management, Inc. | Passiv (13G/A) | 14,50 % | 17.716.372 | -1,50 pp | |
| 14.11.2025 | T. Rowe Price Investment Management, Inc. | Passiv (13G/A) | 16,00 % | 19.097.373 | +1,30 pp | |
| 10.11.2025 | STATE STREET CORPORATION | Passiv (13G) | 4,70 % | 5.617.334 | Neu | |
| 14.08.2025 | T. Rowe Price Investment Management, Inc. | Passiv (13G/A) | 14,70 % | 17.602.440 | +3,40 pp | |
| 07.08.2025 | Abigail P. Johnson (+1) | Passiv (13G/A) | 10,90 % | 13.101.596 | +1,50 pp | |
| 07.05.2025 | T. Rowe Price Investment Management, Inc. | Passiv (13G) | 11,30 % | 13.420.144 | +3,10 pp | |
| 12.02.2025 | Abigail P. Johnson (+1) | Passiv (13G/A) | 9,40 % | 11.146.954 | Neu | |
| 08.01.2025 | The Vanguard Group | Passiv (13G/A) | 10,09 % | 11.915.821 | +0,10 pp | |
| 14.11.2024 | T. Rowe Price Investment Management, Inc. | Passiv (13G) | 8,20 % | 9.689.987 | Neu | |
| 12.11.2024 | . BlackRock, Inc. | Passiv (13G/A) | 13,00 % | 15.252.905 | 0,00 pp | |
| 12.11.2024 | The Vanguard Group | Passiv (13G/A) | 9,99 % | 11.761.605 | 0,00 pp | |
| 04.11.2024 | The Vanguard Group | Passiv (13G/A) | 9,99 % | 11.761.605 | -1,25 pp | |
| 23.10.2024 | . BlackRock, Inc. | Passiv (13G/A) | 13,00 % | 15.252.905 | -3,40 pp | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 11,24 % | 11.016.889 | +0,60 pp | |
| 08.02.2024 | Wellington Management Company LLP | Passiv (13G/A) | 6,45 % | 6.325.032 | -0,22 pp | |
| 08.02.2024 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G/A) | 6,66 % | 6.530.884 | -0,25 pp | |
| 25.01.2024 | : STATE STREET CORPORATION | Passiv (13G/A) | 6,01 % | 0 | +0,68 pp | |
| 22.01.2024 | . BlackRock, Inc. | Passiv (13G/A) | 16,40 % | 16.102.070 | -0,30 pp | |
| 10.02.2023 | . BlackRock, Inc. | Passiv (13G/A) | 16,70 % | 15.767.874 | +0,70 pp | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 10,64 % | 10.073.094 | +0,34 pp | |
| 06.02.2023 | Wellington Management Company LLP | Passiv (13G) | 6,67 % | 6.312.435 | Neu | |
| 06.02.2023 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G) | 6,91 % | 6.542.724 | Neu | |
| 03.02.2023 | : STATE STREET CORPORATION | Passiv (13G/A) | 5,33 % | 0 | +0,58 pp | |
| 26.01.2023 | . BlackRock, Inc. | Passiv (13G/A) | 16,00 % | 14.967.317 | 0,00 pp | |
| 20.01.2023 | . BlackRock, Inc. | Passiv (13G/A) | 16,00 % | 14.967.317 | +0,60 pp | |
| 08.04.2022 | The Vanguard Group | Passiv (13G/A) | 10,30 % | 8.741.124 | +1,97 pp | |
| 14.02.2022 | DRIEHAUS CAPITAL MANAGEMENT LLC | Passiv (13G/A) | 2,77 % | 2.327.112 | +2,77 pp | |
| 09.02.2022 | The Vanguard Group | Passiv (13G/A) | 8,33 % | 6.989.719 | +1,52 pp | |
| 09.02.2022 | : STATE STREET CORPORATION | Passiv (13G/A) | 4,75 % | 0 | -1,81 pp | |
| 27.01.2022 | . BlackRock, Inc. | Passiv (13G/A) | 15,40 % | 12.950.964 | 0,00 pp | |
| 26.01.2022 | . BlackRock, Inc. | Passiv (13G) | 15,40 % | 12.950.964 | -1,00 pp |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 30.06.2026 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 09.10.2025 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 17.06.2025 | Lisa McClain | – | House | Verkauf | $1,001 – $15,000 |
| 11.06.2025 | Lisa McClain | – | House | Kauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | – | -206.031.000 $ | -1,67 $ | 1.273.478.000 $ | -826.568.000 $ |
| 2025-12-31 | 10-K | – | -784.955.000 $ | -6,54 $ | 1.424.537.000 $ | -659.625.000 $ |
| 2025-09-30 | 10-Q | – | -306.178.000 $ | -2,55 $ | 1.436.557.000 $ | -521.123.000 $ |
| 2025-06-30 | 10-Q | – | -134.370.000 $ | -1,12 $ | 1.225.635.000 $ | -368.720.000 $ |
| 2025-03-31 | 10-Q | – | -161.376.000 $ | -1,36 $ | 1.264.051.000 $ | -266.413.000 $ |
| 2024-12-31 | 10-K | – | -589.526.000 $ | -5,26 $ | 1.401.673.000 $ | -135.372.000 $ |
| 2024-12-31 | 10-Q | – | – | – | 1.401.673.000 $ | -135.372.000 $ |
| 2024-09-30 | 10-Q | – | -160.545.000 $ | -1,36 $ | 1.436.060.000 $ | -13.911.000 $ |
| 2024-06-30 | 10-Q | – | -143.318.000 $ | -1,31 $ | 1.523.788.000 $ | 108.550.000 $ |
| 2024-03-31 | 10-Q | – | -135.643.000 $ | -1,33 $ | 808.082.000 $ | -396.160.000 $ |
| 2023-12-31 | 10-K | – | -526.244.000 $ | -5,45 $ | 824.316.000 $ | -386.323.000 $ |
| 2023-09-30 | 10-Q | – | -129.422.000 $ | -1,35 $ | 740.614.000 $ | -438.801.000 $ |
| 2023-06-30 | 10-Q | – | -128.637.000 $ | -1,34 $ | 779.899.000 $ | -333.115.000 $ |
| 2023-03-31 | 10-Q | – | -131.289.000 $ | -1,38 $ | 889.815.000 $ | -229.020.000 $ |
| 2022-12-31 | 10-K | – | -388.955.000 $ | -4,33 $ | 1.014.775.000 $ | -107.900.000 $ |
| 2022-09-30 | 10-Q | – | -142.310.000 $ | -1,52 $ | 1.075.961.000 $ | -15.977.000 $ |
| 2022-06-30 | 10-Q | – | -19.820.000 $ | -0,23 $ | 771.717.000 $ | 111.414.000 $ |
| 2022-03-31 | 10-Q | – | -89.445.000 $ | -1,05 $ | 856.253.000 $ | 116.261.000 $ |
| 2021-12-31 | 10-K | – | -215.314.000 $ | -2,80 $ | 841.319.000 $ | 243.863.000 $ |
| 2021-09-30 | 10-Q | – | -76.086.000 $ | -0,95 $ | 827.539.000 $ | 249.020.000 $ |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| License And Milestone Revenues | 79,4 Mio. | 15,0 Mio. | – | – | – | 90,1 % | +429,0% | |
| Collaboration Revenues | 8,7 Mio. | 3,5 Mio. | – | – | – | 9,9 % | +150,0% | |
| Research And Development | – | – | 4,0 Mio. | 6,6 Mio. | 10,6 Mio. | – | – | |
| Milestone | – | – | 3,5 Mio. | 1,0 Mio. | 5,0 Mio. | – | – | |
| Realization Of Revenue Participation Right Purchase Agreement | – | – | – | 87,0 Mio. | – | – | – | |
| License | – | – | – | – | 54,9 Mio. | – | – |
Quartalsverlauf
| Segment | Q3 FY2025 | Q2 FY2025 | Q3 FY2024 | Q2 FY2024 | Q1 FY2024 | Q3 FY2023 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenues | 1,9 Mio. | 2,4 Mio. | – | – | – | – | 100,0 % | Neu | |
| License And Milestone Revenues | – | 64,4 Mio. | – | – | – | – | – | – | |
| Research And Development | – | – | 463.000 | 249.000 | 835.000 | 378.000 | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 05.05.2026 | 19,4 Mio. USD | -1,67 |
| Q3 2025 | 30.09.2025 | 05.11.2025 | 1,9 Mio. USD | -2,55 |
| Q2 2025 | 30.06.2025 | 07.08.2025 | 66,8 Mio. USD | -1,12 |
| Q1 2025 | 31.03.2025 | 06.05.2025 | 1,6 Mio. USD | -1,36 |
| Q3 2024 | 30.09.2024 | 07.11.2024 | 463.000 USD | -1,36 |
| Q2 2024 | 30.06.2024 | 09.08.2024 | 249.000 USD | -1,31 |
| Q1 2024 | 31.03.2024 | 10.05.2024 | 835.000 USD | -1,33 |
| Q3 2023 | 30.09.2023 | 03.11.2023 | 378.000 USD | -1,35 |
| Q2 2023 | 30.06.2023 | 03.08.2023 | 867.000 USD | -1,34 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 05.05.2026 | 10-Q | 31.03.2026 | 35 Tage | SEC » |
| 26.02.2026 | 10-K | 31.12.2025 | 57 Tage | SEC » |
| 05.11.2025 | 10-Q | 30.09.2025 | 36 Tage | SEC » |
| 07.08.2025 | 10-Q | 30.06.2025 | 38 Tage | SEC » |
| 06.05.2025 | 10-Q | 31.03.2025 | 36 Tage | SEC » |
| 27.02.2025 | 10-K | 31.12.2024 | 58 Tage | SEC » |
| 07.11.2024 | 10-Q | 30.09.2024 | 38 Tage | SEC » |
| 09.08.2024 | 10-Q | 30.06.2024 | 40 Tage | SEC » |
| 10.05.2024 | 10-Q | 31.03.2024 | 40 Tage | SEC » |
| 28.02.2024 | 10-K | 31.12.2023 | 59 Tage | SEC » |
| 03.11.2023 | 10-Q | 30.09.2023 | 34 Tage | SEC » |
| 03.08.2023 | 10-Q | 30.06.2023 | 34 Tage | SEC » |
| 05.05.2023 | 10-Q | 31.03.2023 | 35 Tage | SEC » |
| 01.03.2023 | 10-K | 31.12.2022 | 60 Tage | SEC » |
| 04.11.2022 | 10-Q | 30.09.2022 | 35 Tage | SEC » |
| 05.08.2022 | 10-Q | 30.06.2022 | 36 Tage | SEC » |
| 06.05.2022 | 10-Q | 31.03.2022 | 36 Tage | SEC » |
| 25.02.2022 | 10-K | 31.12.2021 | 56 Tage | SEC » |
| 05.11.2021 | 10-Q | 30.09.2021 | 36 Tage | SEC » |
| 06.08.2021 | 10-Q | 30.06.2021 | 37 Tage | SEC » |
| 07.05.2021 | 10-Q | 31.03.2021 | 37 Tage | SEC » |
| 11.03.2021 | 10-Q/A | 30.09.2020 | 162 Tage | SEC » |
| 26.02.2021 | 10-K | 31.12.2020 | 57 Tage | SEC » |
| 06.11.2020 | 10-Q | 30.09.2020 | 37 Tage | SEC » |
| 07.08.2020 | 10-Q | 30.06.2020 | 38 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 07.05.2026 | Kapitalerhöhung | $700,0 Mio · $71,00/Aktie | SEC » |
| 05.05.2026 | Kapitalerhöhung | $650,0 Mio | SEC » |
| 24.05.2024 | Kapitalerhöhung | $490,2 Mio · $51,00/Aktie | SEC » |
| 22.05.2024 | Kapitalerhöhung | $500,0 Mio | SEC » |
| 01.03.2023 | Kapitalerhöhung | $300,0 Mio | SEC » |
| 21.07.2021 | Kapitalerhöhung | $275,0 Mio · $27,50/Aktie | SEC » |
| 19.07.2021 | Kapitalerhöhung | $200,0 Mio | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 17.04.2026 | HV-Einladung | 27.05.2026 Jahres-HV | 31.03.2026 | DEF 14A | SEC » |
| 10.04.2025 | HV-Einladung | 14.05.2025 Jahres-HV | 24.03.2025 | DEF 14A | SEC » |
| 31.03.2025 | Vorläufig | — | — | PRE 14A | SEC » |
| 08.04.2024 | HV-Einladung | 15.05.2024 Jahres-HV | 26.03.2024 | DEF 14A | SEC » |
| 07.04.2023 | HV-Einladung | 10.05.2023 Jahres-HV | 21.03.2023 | DEF 14A | SEC » |
| 27.03.2023 | Vorläufig | — | — | PRE 14A | SEC » |
| 08.04.2022 | HV-Einladung | 10.05.2022 Jahres-HV | 21.03.2022 | DEF 14A | SEC » |
| 07.04.2021 | HV-Einladung | 12.05.2021 Jahres-HV | 22.03.2021 | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 14.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 20.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 11.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 16.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 07.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 15.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 17.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 26.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 02.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 24.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 27.05.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 08.04.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 01.03.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 24.02.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 19.02.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 27.05.2026 | HV-Abstimmung | 0,00 | 20 | Jahreshauptversammlung vom 27. Mai 2026 mit hoher Beteiligung (93,47%). Abstimmungsergebnisse zu Tagesordnungspunkten eingereicht. | SEC |
| 05.05.2026 | Quartalszahlen | 0,10 | 55 | Cytokinetics veröffentlicht Finanzergebnisse für das erste Quartal 2026 (zum 31. März). Die vollständigen Ergebnisse finden sich im beigefüg… 🔒 | SEC |
| 05.05.2026 | Sonstiges | 0,00 | 10 | Cytokinetics hat eine Corporate Presentation als Exhibit eingereicht. Das 8-K enthält keine wesentlichen Geschäftsereignisse oder Ankündigun… 🔒 | SEC |
| 24.02.2026 | Quartalszahlen | 0,00 | 45 | Cytokinetics gab Finanzergebnisse für Q4 und das Geschäftsjahr 2025 am 24. Februar 2026 bekannt. Weitere Details aus der Pressemitteilung li… 🔒 | SEC |
| 17.02.2026 | Behördliche Maßnahme | 0,80 | 87 | Cytokinetics kündigte an, dass die Europäische Kommission MYQORZO® (aficamten) zur Behandlung der symptomatischen obstruktiven Hypertrophie-… 🔒 | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 19.989 | 87,26 | 1.744.240 |
| 2026-06-29 | 31.203 | 82,19 | 2.564.575 |
| 2026-06-24 | 2.276 | 80,01 | 182.103 |
| 2026-06-22 | 17.045 | 78,78 | 1.342.805 |
| 2026-06-17 | 2.128 | 75,21 | 160.047 |
| 2026-06-15 | 1.750 | 70,15 | 122.763 |
| 2026-06-08 | 3.066 | 71,48 | 219.158 |
| 2026-05-26 | 2.077 | 76,94 | 159.804 |
| 2026-05-21 | 263.848 | 78,77 | 20.783.307 |
| 2026-05-20 | 65 | 76,45 | 4.969 |
| 2026-05-19 | 98 | 75,18 | 7.368 |
| 2026-05-18 | 355 | 75,85 | 26.927 |
| 2026-05-15 | 6.306 | 78,64 | 495.904 |
| 2026-05-14 | 45 | 77,22 | 3.475 |
| 2026-05-13 | 27.719 | 74,81 | 2.073.658 |
| 2026-05-11 | 4 | 76,91 | 308 |
| 2026-05-08 | 2.437.516 | 74,29 | 181.083.064 |
| 2026-05-07 | 874 | 74,84 | 65.410 |
| 2026-05-06 | 274.693 | 77,09 | 21.176.083 |
| 2026-05-05 | 7.318 | 66,05 | 483.354 |
| 2026-05-01 | 4.607 | 63,97 | 294.710 |
| 2026-04-30 | 6.902 | 59,58 | 411.221 |
| 2026-04-28 | 10.929 | 61,60 | 673.226 |
| 2026-04-23 | 75 | 66,25 | 4.969 |
| 2026-04-22 | 822 | 65,80 | 54.088 |
| 2026-04-15 | 1.020 | 66,35 | 67.677 |
| 2026-04-14 | 1 | 66,72 | 67 |
| 2026-04-10 | 746 | 64,59 | 48.184 |
| 2026-04-08 | 12.406 | 65,48 | 812.345 |
| 2026-04-06 | 95.167 | 66,73 | 6.350.494 |
| 2026-04-01 | 4 | 65,91 | 264 |
| 2026-03-31 | 419 | 62,97 | 26.384 |
| 2026-03-30 | 69 | 62,50 | 4.313 |
| 2026-03-27 | 668 | 63,48 | 42.405 |
| 2026-03-26 | 369 | 62,39 | 23.022 |
| 2026-03-25 | 25.106 | 60,02 | 1.506.862 |
| 2026-03-24 | 2 | 60,95 | 122 |
| 2026-03-23 | 1.619 | 61,70 | 99.892 |
| 2026-03-20 | 400 | 62,95 | 25.180 |
| 2026-03-18 | 27 | 62,13 | 1.678 |
| 2026-03-10 | 242 | 62,42 | 15.106 |
| 2026-03-06 | 521 | 62,19 | 32.401 |
| 2026-02-27 | 55.565 | 62,63 | 3.480.036 |
| 2026-02-26 | 4.625 | 62,89 | 290.866 |
| 2026-02-24 | 82.065 | 68,26 | 5.601.757 |
| 2026-02-20 | 2 | 67,83 | 136 |
| 2026-02-19 | 4.620 | 66,98 | 309.448 |
| 2026-02-17 | 3.573 | 66,26 | 236.747 |
| 2026-02-13 | 5.694 | 65,04 | 370.338 |
| 2026-02-12 | 320 | 66,80 | 21.376 |
| 2026-02-11 | 78 | 64,85 | 5.058 |
| 2026-02-03 | 10 | 65,16 | 652 |
| 2026-01-30 | 96 | 65,60 | 6.298 |
| 2026-01-29 | 434 | 65,14 | 28.271 |